



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# **COVID-19 Situational Update**

---

**Jennifer A. Shuford, MD, MPH**

**Interim Commissioner**

**Texas Department of State Health Services**

**October 3, 2022**

# DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. Information is subject to change.

October 03, 2022



**TEXAS**  
Health and Human  
Services

---

Texas Department of State  
Health Services

# **COVID-19 Snapshot**

---

# Snapshot: COVID-19 in Texas

---

As of September 29, 2022

- Total Cases
  - 6,350,452
  - 7-day average for new daily cases is decreasing
- Current Hospitalizations
  - 1,706 (decreasing)
- Total Fatalities
  - 89,185
  - 7-day average of new fatalities is slowly increasing
- Molecular Positivity Rate
  - 9.70% (decreasing)



TEXAS  
Health and Human Services

Texas Department of State  
Health Services



**TEXAS**  
Health and Human  
Services

---


Texas Department of State  
Health Services

# **COVID-19 Trends**

---

## Texas New Cases per Day


Pop: 29.7M; Slope: -88.3; 100k: -0.3; 7 Day Avg: 1,769.7; 7/14 Day Avg  $\Delta$ : -83.2/-127.1



Blue line is 7 Day Moving Average.  $\Delta$  is the change in the 7 Day Moving Average over a 7 or 14 day period.  
These preliminary data are current as of 09/29/2022


## Texas Hospitalizations Over Time

Pop: 29.7M; Slope: -40.4; 100k: -0.1; 7 Day Avg: 1,797.7; 7/14 Day Avg  $\Delta$ : -38.8/-36.6




Blue line is 7 Day Moving Average.  $\Delta$  is the change in the 7 Day Moving Average over a 7 or 14 day period.  
These preliminary data are current as of Thu Sep 29 12:55:24 2022

# Statewide: 7-Day Rolling Average of 24-Hour Lab Confirmed COVID Hospital Admission Rate by Age per 100,000 population 12/01-2020 – 09/28/2022



## Texas New Fatalities per Day



Pop: 29.7M; Slope: 0.1; 100k: 0; 7 Day Avg: 19.6; 7/14 Day Avg  $\Delta$ : -0.1/0





Blue line is 7 Day Moving Average.  $\Delta$  is the change in the 7 Day Moving Average over a 7 or 14 day period.  
Preliminary data as of 09/29/2022. Data source are New Fatalities by Date Recorded.  
Last date of data is 09/29/2022

# Demographic Data 2020 – 2022

## Case Demographic Data




## Fatality Demographic Data




# COVID-19 Variants: National Surveillance Data

## 6/19-2022 – 9/24/2022



# COVID-19 Variants: Texas Surveillance Data

## 5/22/2022 – 9/17/2022



**Data Source:** Centers for Disease Control and Prevention (CDC) Commercial Partner Laboratories and Texas Department of State Health Services (DSHS) Austin Laboratory, last updated 09/27/2022

**Additional Resources:** CDC COVID-19 National Genomic Surveillance Dashboard <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/genomic-surveillance-dashboard.html>, SARS-CoV-2 (hCoV-19) Mutation Situation Reports <https://outbreak.info/situation-reports>, Nextstrain SARS-CoV-2 resources <https://nextstrain.org/sars-cov-2/>, CoVariants <https://covariants.org/>, PANGO Lineage Reports [https://cov-lineages.org/global\\_report.html](https://cov-lineages.org/global_report.html)



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

# **Texas CARES Project**

---

# Texas CARES Project




TEXAS

Health and Human Services

Texas Department of State  
Health Services

- A collaboration between Texas Department of State Health Services and UTHealth Houston, the Texas **C**oronavirus **A**ntibody **R**esponse Survey (Texas CARES) measures the percentage of participants who have antibodies to SARS-CoV-2 virus in their blood.
  - This measurement is called "seroprevalence".
- All Texans 5-90 years of age can participate in the survey.
- There are currently 85,972 participants in the study.
- **As of March 1, 2022, 99.82%** of the study participants were seropositive of SARS-CoV-2 antibodies either from past COVID-19 infection and/or vaccination.

**Fig 2. [Updated] Estimated natural- and vaccine-induced antibodies in Texas (i.e., weekly percentage of naturally occurring antibodies or fully vaccinated individuals).**




DeSantis SM, León-Novelo LG, Swartz MD, Yaseen AS, Valerio-Shewmaker MA, et al. (2022) Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region. PLOS ONE 17(9): e0273694.

<https://doi.org/10.1371/journal.pone.0273694> <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0273694>

# Texas CARES Project

- The seropositivity continues to remain very high among study participants.
- **As of September 4, 2022, 99%** of the study participants were seropositive of SARS-CoV-2 antibodies either from past COVID-19 infection and/or vaccination.



TEXAS  
Health and Human Services

Texas Department of State  
Health Services



**TEXAS**  
Health and Human  
Services

---

Texas Department of State  
Health Services

# **COVID-19 Therapeutics**

---

# Texas COVID-19 Therapeutics

## Allocations & Orders as of September 23, 2022:

- One monoclonal antibody treatment for high-risk patients (**55,595** patient courses allocated)
- One pre-exposure monoclonal antibody for immunocompromised patients (**38,256** cartons\* allocated)
- Two oral antiviral treatments for high-risk patients (**937,688** patient courses shipped to Texas)
- DSHS-supported Mobile Infusion Center (**100,064** treatments administered)
- All state-supported Regional Infusion Centers and mobile teams (**171,810** total treatments administered)



TEXAS

Health and Human Services

Texas Department of State  
Health Services

\*Evusheld is supplied in cartons that contain one 150 mg/1.5 mL vial of tixagevimab and one 150 mg/1.5 mL vial of cilgavimab.

# Texas COVID-19 Therapeutics

---

- Texas continues to have ample supply of COVID-19 therapeutics available in many locations across the state
  - This includes Paxlovid (nirmatrelvir/ritonavir), the first line treatment for COVID-19 and Lagevrio (molnupiravir) which is an alternative oral treatment
- The U.S. Department of Health and Human Services is starting the process of transitioning additional COVID-19 therapeutics to the commercial market
  - Both Remdesivir (an IV antiviral medication) and Bebtelovimab (a monoclonal antibody) are available for commercial purchase



TEXAS  
Health and Human Services

Texas Department of State  
Health Services



**TEXAS**  
Health and Human  
Services

---

**Texas Department of State  
Health Services**

**Thank you!**

---